MarketScreener Homepage > Equities > Nasdaq > VYNE Therapeutics Inc. VYNE

Report

Delayed Nasdaq - 01/19 04:00:00 pm
1.78	USD		+6.59%

01/07

VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

01/05

VYNE THERAPEUTICS : to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event this Week

2020

VYNE THERAPEUTICS : Completes End-of-Phase 2 Meeting With FDA for FCD105 to Treat Acne

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq

01/12/2021	01/13/2021	01/14/2021	01/15/2021	01/19/2021	Date
1.65(c)	1.63(c)	1.65(c)	1.67(c)	1.78	Last
1 319 182	1 038 283	1 269 878	1 571 494	3 844 624	Volume
+1.85%	-1.21%	+1.23%	+1.21%	+6.59%	Change

More quotes

Financials (USD)

Sales 2020	21,9 M - -
Net income 2020	-206 M - -
Net Debt 2020	- - -
P/E ratio 2020	-0,87x
Yield 2020	-

Sales 2021	61,9 M - -
Net income 2021	-79,1 M - -
Net Debt 2021	- - -
P/E ratio 2021	-3,98x
Yield 2021	-

Capitalization	280 M 280 M -
Capi. / Sales 2020	12,8x
Capi. / Sales 2021	4,53x
Nbr of Employees	40
Free-Float	-

More Financials

Company

Vyne Therapeutics Inc., formerly Menlo Therapeutics Inc., is a biopharmaceutical company. The Company is focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions, such as atopic dermatitis, psoriasis and prurigo nodularis. The Company is focused on developing and commercializing a variety of solutions using its Molecule Stabilizing...

Sector

Calendar

More about the company

Notations Surperformance© of VYNE Therapeutics Inc.

Trading Rating :

Investor Rating :

More Ratings

All news about VYNE THERAPEUTICS INC.

01/07	VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhi..	AQ
01/05	VYNE THERAPEUTICS : to Present at the LifeSci Partners 10th Annual Healthcare Co..	AQ
2020	VYNE THERAPEUTICS : Completes End-of-Phase 2 Meeting With FDA for FCD105 to Trea..	MT
2020	VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for ..	GL
2020	VYNE THERAPEUTICS : to Join Nasdaq Biotechnology Index	MT
2020	VYNE THERAPEUTICS : Added to Nasdaq Biotechnology Index	AQ
2020	VYNE THERAPEUTICS : Wins US Patent for Acne Treatment Amzeeq	MT
2020	VYNE THERAPEUTICS : Announces New U.S. Patent Expiring in 2037 for AMZEEQ® (mino..	AQ
2020	VYNE Therapeutics Announces Publication of Long-term Safety & Efficacy Data f..	GL
2020	VYNE THERAPEUTICS : to Present at the 32nd Annual Piper Sandler Healthcare Confe..	AQ
2020	VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conf..	GL
2020	VYNE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition ..	AQ
2020	VYNE THERAPEUTICS INC. : Results of Operations and Financial Condition (form 8-K..	AQ
2020	Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 EPS $-0.13, vs. Street Est o..	MT
2020	Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q3 Revenue $3.3M, vs. Street ..	MT

More news

News in other languages on VYNE THERAPEUTICS INC.

- No features available -

More news

Provided by Scoopnest.com

Chart VYNE THERAPEUTICS INC.

Duration : Period :

VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener

Full-screen chart

Technical analysis trends VYNE THERAPEUTICS INC.

	Short Term	Mid-Term	Long Term
Trends	Bearish	Neutral	Neutral

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	BUY
Number of Analysts	7
Average target price	5,93 $
Last Close Price	1,67 $
Spread / Highest target	499%
Spread / Average Target	255%
Spread / Lowest Target	79,6%

Consensus

EPS Revisions

More Estimates Revisions